Radiosensitizers and Radiochemotherapy in the Treatment of Cancer

Radiosensitizers and Radiochemotherapy in the Treatment of Cancer

By (author) 
Free delivery worldwide Expected delivery to the United States in 8-13 business days.
Not ordering to the United States? Click here.
Order now for expected delivery to the United States by Christmas Order now for expected delivery to the United States by Christmas


Radiosensitizers and Radiochemotherapy in the Treatment of Cancer catalogs and describes the mechanism of action for entities characterized as radiosensitizers. Developments in the biological and physical sciences have introduced new radiosensitizers and defined novel targets for radiosensitization. As a result, a book about radiosensitization must now address a huge range of topics, covering everything from molecular oxygen and high Z elements to monoclonal antibodies and complex phytochemicals.

At the molecular level, the understanding of the molecular consequences of DNA damage and the DNA damage response have informed the development of targeted radiosensitizers and shed light on the mode of action of radiochemotherapy protocols of known clinical efficacy.

In this book the mechanisms of action at the molecular and cellular level are described for documented radiosensitizers including, where applicable, a brief history of their clinical use and most recent clinical results. In addition, the clinical context is addressed including the importance of factors such as dose and dose rate, normal tissue toxicity, and drug delivery. Intuitively organized by topic and application, the book includes extensive illustrations, end-of-chapter summaries, and a wealth of references.
show more

Product details

  • Paperback | 548 pages
  • 156 x 234 x 22.86mm | 1,012g
  • CRC Press
  • London, United Kingdom
  • English
  • 0367378027
  • 9780367378028

Table of contents

Radiosensitization and Chemoradiation. Radiosensitization by Oxygen and Nitric Oxide. Radioenhancement by Targeting Cellular Redox Pathways and/or by Incorporation of High-Z Materials into the Target. Radiosensitization by Halogenated Pyrimidines. Radiosensitization by Antimetabolites. Radiosensitization by Platinum Drugs and Alkylating Agents. Topoisomerase Inhibitors and Microtubule-Targeting Agents. Targeting the DNA Damage Response: ATM, p53, Checkpoints, and the Proteasome. Radiosensitization by Inhibition of DNA Repair. Targeting Growth Factor Receptors for Radiosensitization. Targeting Signaling Molecules for Radiosensitization. Radiosensitization by Targeting the Tumor Microenvironment. Phytochemicals: Chemopreventive, Radiosensitizing, Radioprotective. Delivery Methods for Radioenhancing Drugs.
show more

Review quote

"This book is intended for both graduate students and seasoned researchers seeking a detailed review covering the therapeutic benefits of a combination of radiotherapy and drugs that alter the metabolism of cancer cells and their response to radiation. The summary at the end of each chapter targets the important points and directs the reader to the sections that are most relevant to him. Although preclinical studies are widely documented, the author took care to establish the links with clinical trials to appreciate the real impact of the various combinations of radio- and chemotherapy."
--Benoit Paquette, Professor and Head of the Department of Nuclear Medicine and Radiobiology, University of Sherbrooke

"This book is a great contribution to the field of radiation biology, examining the mechanisms of action, clinical uses, and targeting of radiation response modifiers, both radioprotectors and radiosensitizers. The depth and breadth of information covered in this text is exceptional and will be useful to oncologists, radiation oncologists, radiation biologists, medical physicists, and other radiation workers who seek to use radiation response modifiers in association with cancer therapy. This book will be useful in the clinical setting as well as in graduate school classrooms around the world."
--Gayle E. Woloschak, Department of Radiation Oncology, Northwestern University
show more

About Shirley Lehnert

Shirley Lehnert is currently a professor in the Department of Oncology at McGill University in Montreal, Quebec, Canada. She graduated from London University in the UK with a PhD in biophysics. Dr. Lehnert did postdoctoral work at the University of Rochester. She conducted research in radiobiology and biophysics first at Sloane Kettering Institute and then at the Radiological Research Laboratory of Columbia University in New York. Dr. Lehnert has published extensively in the fields of radiation biology, tumor biology, and drug delivery.
show more